Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Mar 9, 2026, 4:00 PM EDT
1.050
+0.020 (1.94%)
After-hours: Mar 9, 2026, 4:46 PM EDT
Cocrystal Pharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
14.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOCP News
- 9 hours ago - First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire
- 18 days ago - Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 - GlobeNewsWire
- 2 months ago - Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - GlobeNewsWire
- 3 months ago - Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 4 months ago - Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program - GlobeNewsWire
- 5 months ago - Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference - GlobeNewsWire